Insilico Medicine
AI platform that designs new drugs and licenses them to big pharma.
The call
Insilico is growing fast on pharma deals and a strong cash position, but rentosertib's Phase III result and Isomorphic Labs' next big contract will decide its next chapter.
Insilico Medicine uses artificial intelligence to design new drugs faster and cheaper than traditional methods. It has already gotten FDA approval for an AI-designed molecule and has deals with major pharmaceutical companies, which makes it harder for newcomers to compete. The biggest challenge is that Isomorphic Labs, a well-funded AI company backed by Google's DeepMind, is chasing the same pharmaceutical customers with similar technology and has already signed major deals worth billions of dollars. The company's fate also hinges on whether its lead drug candidate, rentosertib, succeeds in clinical trials over the next year or so, because a failure would hurt investor confidence significantly.
Why
01
AI pressure: Isomorphic Labs. Isomorphic uses AlphaFold-based AI to sign Lilly and Novartis deals worth $2.9B, competing directly for the same pharma dollars. Could AI do the core job? Only partly.
02
Bigger players: Eli Lilly, Takeda, Servier. These pharma partners pay Insilico now but could build AI discovery in-house over time, cutting future licensing fees. Could a giant copy it? Probably.
03
What protects it. Its multi-omics data, an FDA/CDE-cleared AI-designed molecule, and locked-in pharma workflows are hard for rivals to copy fast.
What would change this call
Isomorphic Labs announces a $3B+ exclusive deal with a top-5 pharma before rentosertib Phase III readout. Would show Insilico's platform pricing power eroding against a better-funded rival.
Rentosertib Phase III (320 patients, 52-week FVC endpoint) safety or efficacy readout, expected within 12-18 months. Would confirm or undercut Insilico's core clinical proof-of-concept for its AI-designed drug.
Eli Lilly, Takeda, or Servier disclose building internal AI-discovery capability instead of renewing with Insilico. Would show pharma partners shifting from licensing Insilico's platform to in-house alternatives.
Rentosertib Phase III (320 patients, 52-week FVC endpoint) safety or efficacy readout, expected within 12-18 months. Would confirm or undercut Insilico's core clinical proof-of-concept for its AI-designed drug.
Eli Lilly, Takeda, or Servier disclose building internal AI-discovery capability instead of renewing with Insilico. Would show pharma partners shifting from licensing Insilico's platform to in-house alternatives.
Key numbers
- H1 2026 revenue guided $102.5M-$106.5M, up ~280% YoY
- Lilly deal worth up to $2.75 billion signed
- Cash and bank balances of $393.3 million post-IPO
Named risks
- Rentosertib Phase III (320 patients, initiated July 7, 2026) could fail or show enrollment/safety issues within 12-18 months.
- Isomorphic Labs could sign a $3B+ exclusive deal with a top-5 pharma before rentosertib readout, eroding platform pricing power.
- Heavy reliance on China-based Phase III trial infrastructure amid US-China biotech tensions.
- Headcount figures conflict sharply across sources (90 to 350 employees), suggesting data quality or rapid volatility.
- Open-weight chemistry models could commoditize platform licensing revenue within 18 months.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Isomorphic Labs | contesting | Signed Lilly and Novartis deals worth up to $2.9B combined as of June 2026, same pharma customers as Insilico |
| Recursion Pharmaceuticals | contesting | Merged with Exscientia in 2024, competing phenotypic-screening plus ML approach to drug discovery |
| Schrodinger | contesting | Physics-based molecular modeling rival cited in June 2026 oncology comparison |
| Eli Lilly internal AI programs | gaining on | Big pharma building internal AI discovery capability, a slow threat to platform licensing even while Lilly remains a $2.75B customer as of March 2026 |
Questions people ask
- Is Insilico Medicine profitable in 2026?
- Yes, per its own July 8, 2026 profit alert Insilico expects H1 2026 net profit of US$33.5M to US$39.5M on revenue of US$102.5M to US$106.5M, a swing from a US$19.2M net loss in H1 2025, per Insilico Medicine.
- Who owns Insilico Medicine and is it public?
- Insilico Medicine is publicly listed on the Hong Kong Stock Exchange under ticker 3696 after its IPO on December 30, 2025, which raised HKD 2.277 billion (about US$291 to 293 million), the largest HK biotech IPO of 2025.
- Who is Insilico Medicine's biggest competitor?
- Isomorphic Labs, the DeepMind spinout, is Insilico's biggest rival for pharma partnership dollars; it has raised about US$2.7 billion and signed deals with Eli Lilly and Novartis worth up to US$2.9 billion combined, as of June 2026.
- Could AI replace Insilico Medicine's own business?
- Unlikely outright since Insilico's business is AI drug discovery itself, but generative chemistry could commoditize; its defense is proprietary multi-omics data since 2014, FDA/CDE clearance for rentosertib, and embedded pharma partnerships like the March 2026 Lilly deal.
- Is joining Insilico Medicine as an employee risky?
- Headcount estimates vary from about 90 to 350 across sources as of mid-2026, but the company is newly profitable, cash-rich with US$393.3 million as of December 31, 2025, and has major deals with Lilly and Takeda, though its flagship drug faces a binary Phase III readout.
- What is rentosertib and why does it matter for Insilico Medicine?
- Rentosertib is Insilico's TNIK inhibitor for idiopathic pulmonary fibrosis, billed as the first wholly AI-discovered-and-designed small molecule; it entered a 320-patient Phase III trial on July 7, 2026, after positive Phase IIa results published in Nature Medicine in 2025.
Timeline
- 2026-07-08Positive profit alert: H1 2026 revenue US$102.5M-106.5M, net profit US$33.5M-39.5M
- 2026-07-07Initiated Phase III trial for rentosertib, 320 patients, 47 centers in China
- 2026-07-01Announced strategic AI drug-discovery collaboration with Takeda
- 2026-05-01Announced longevity foundation model collaboration with Human Life Foundation
- 2026-03-29Announced Eli Lilly collaboration worth up to US$2.75 billion; FY2025 results released
- 2026-03-26Named #3 Most Innovative Biotech Company on Fast Company's 2026 list
- 2026-03-01Liquid AI joint deployment achieved state-of-the-art results on Science MMAI Gym
- 2026-01-01Launched Science MMAI Gym foundation-model training framework
- 2025-12-30IPO on Hong Kong Stock Exchange (3696), raising HKD 2.277 billion
Head to head
Revision history
21 July 2026
First assessed. Protection under test. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Insilico Medicine becomes 2025's largest Hong Kong biotech IPO (2026-01-02)
- Insilico Medicine Announces 2025 Annual Results (2026-03-29)
- HKEX Positive Profit Warning filing (2026-07-09)
- Insilico Medicine Releases Positive Profit Alert for the First Half of 2026 (2026-07-08)
- Lilly signs $2.75B deal with Insilico for oral therapeutics (2026-03-29)
- Insilico Medicine - Overview, News & Similar companies (2026-07-06)
- AI Oncology Drug Discovery (2026-06-23)
- Insilico Medicine issues positive profit alert for H1 2026 (2026-07-08)
- Insilico Initiates Phase III Clinical Trial for Rentosertib (2026-07-07)
- Insilico Medicine: The AI Biotech That Wants to Solve Ageing (2026-06-18)
- Insilico Medicine named to Fast Company's 2026 list (2026-03-26)
- Isomorphic Labs entry (2026-06-22)